Home › NDC Lookup › Ingredients › Busulfan › 00409-1112-01
BUSULFAN 6 mg/mL Injection, Solution — NDC 00409-1112-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

BUSULFAN 6 mg/mL Injection, Solution — NDC 0409-1112-01 (Billing 00409-1112-01)

by Hospira, Inc. · 8 CARTON in 1 CARTON / 1 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE

This is a package of BUSULFAN 6 mg/mL Injection, Solution from Hospira, Inc., marketed since Feb 2019 and currently FDA-listed. It is this product's only package size.

NDC 00409-1112-01
🏷️ FDA NDC (as labeled) 0409-1112-01 billing pads the labeler segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0409-1112-01 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0409 labeler · 1112 product · 01 package
Package marketed since
Feb 28, 2019
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0409111201 8
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Busulfan (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · May 4, 2026 — Failed Impurities/Degradation Specifications (Sagent Pharmaceuticals) · FDA recall D-0539-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0409-1112-01
Product NDC 0409-1112
11-digit billing NDC 00409111201
NCPDP billing unit ML — per mL (volume)
RxCUI 253113
UNII G1LN9045DK
Application # ANDA205672
SPL Set ID b9c7f0dc-988d-466e-8031-400ec4f60f21
Established class (EPC) Alkylating Drug
Mechanism of action Alkylating Activity
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-02-28
Route INTRAVENOUS
Dosage form INJECTION, SOLUTION
Substance BUSULFAN
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 21100010002020
GPI class Busulfan
GCN Seq No 063053
GCN 98813
HICL code 003899
Ingredient (HICL) Busulfan
HIC1 code V
Therapeutic class — broad (HIC1) Neoplasms
HIC2 code V1
Therapeutic class — intermediate (HIC2) Antineoplastic Drugs
HIC3 code V1A
Therapeutic class — specific (HIC3) Antineoplastic - Alkylating Agents
AHFS code 10:00.00.00
AHFS class Antineoplastic Agents
FDB label name BUSULFAN 60 MG/10 ML VIAL
FDB brand name Busulfan
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 063053
  • GCN: 98813
  • GPI-14 (Medi-Span): 21100010002020
  • HICL (First Databank): 003899
  • AHFS class code: 10:00.00.00
  • RxCUI (RxNorm): 253113
Why two NDCs? The FDA registers this code as 0409-1112-01 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00409-1112-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Alkylating Drug class.

Pharmacologic class Alkylating Drug
Drug family (ATC) Alkyl sulfonates
How it works Alkylating Activity
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name BUSULFAN 60 MG/10 ML VIAL Ingredient Busulfan
📗 Our plain-language guide HelloPharmacist
  • It treats chronic myelogenous leukemia (CML). Myleran tablets are used to ease the disease, while the IV forms are given with cyclophosphamide to prepare you for a donor stem cell...
  • Myleran is a tablet you take by mouth, usually daily, while your doctor follows your blood counts. Busulfex and Busulfan Injection are given by IV through a central line over 2 hou...
  • Nausea, vomiting, mouth sores, poor appetite, diarrhea, trouble sleeping, and low blood counts are very common. Your team will watch your blood counts closely and treat these as ne...
  • Call right away for fever, bleeding or bruising, a new cough or shortness of breath, yellow skin or eyes, belly swelling, chest pain, or seizures. These can signal serious problems...
📖 Read our full Busulfan guide →
1
Nutrient depletion considerations

Busulfan may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Busulfan nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Medicare Part B allowsASP · J0594 $1.033 / J0594 unit —
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)0409-1112-01
11-digit billing NDC00409-1112-01
Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)
HCPCS J-codeJ0594
DescriptorINJECTION, BUSULFAN, 1 MG
Billing units / pkg6 units
How the units are derivedThis package is 10 ML; the HCPCS unit is 1 MG, so one package = 6 billing units.
Medicare Part B spend (2026 (Q1))$10,642 · 68 claims · $156.51 per claim (all NDCs under J0594)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00409-1112-01 You're viewing this Main listing 8 CARTON in 1 CARTON / 1 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE 2019-02-28 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Busulfan 6 mg/mLthis 00409-1112-01 Hospira, 1 vial — AP FDA listed —
Busulfan 6 mg/mL 16729-0351-92 Accord 8 vials — AP FDA listed —
Busulfan 6 mg/mL 25021-0241-10 Sagent 8 vials — AP FDA listed —
Busulfan 6 mg/mL 51817-0170-01 Pharmascience 8 vials — AP FDA listed —
Busulfan 6 mg/mL 55150-0395-08 Eugia 8 vials — — FDA listed —
Busulfex 6 mg/mL 59148-0070-91 Otsuka 1 vial — AP Discontinued —
Busulfan 6 mg/mL 70121-1244-07 Amneal 8 vials — AP FDA listed —
Busulfan 6 mg/mL 71288-0116-11 Meitheal 8 vials — AP FDA listed —
Busulfan 6 mg/mL 71288-0158-96 Meitheal 8 vials — AP FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
Feb 2019
📍
2026
Currently FDA-listed
7 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Busulfan inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII JCV5VDB3HY
    N,N-Dimethylacetamide is a clear liquid solvent derived from acetic acid and dimethylamine. In medicines, it dissolves or suspends active ingredients to create uniform liquid formulations.
  • UNII B697894SGQ
    Polyethylene glycol 400 is a clear, thick liquid made from petroleum-derived polymers. It acts as a solvent and humectant in medicines, helping dissolve active ingredients and retain moisture in the formulation.

2 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerHospira, Inc.
Application holderHOSPIRA INC
FDA applicationANDA205672 (ANDA)
Labeler code00409
First marketedFeb 2019
Product typeHuman Prescription Drug
Portfolio317 products on file

More NDCs from Hospira, Inc. labeler code 00409

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning 🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients 🧬 Pharmacokinetics 🔬 Clinical Studies 🧪 Nonclinical Toxicology 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📚 References 📄 Package Label / Principal Display Panel
🚨 Boxed Warning 71 words ▾

WARNING: MYELOSUPPRESSION Busulfan Injection causes severe and prolonged myelosuppression at the recommended dosage. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression [see Warnings and Precautions (5.1) ]. WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning.

Causes severe and prolonged myelosuppression. ( 5.1 ) Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression . ( 5.1 )

🎯 Indications and Usage 61 words ▾

1 INDICATIONS AND USAGE Busulfan Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan Injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML). ( 1 )

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION Pre-medicate with anticonvulsants (e.g. benzodiazepines, phenytoin, valproic acid or levetiracetam) and antiemetic. ( 2.1 , 5.2 ) Dilute and administer as intravenous infusion. Do not administer as intravenous push or bolus.

( 2.1 , 2.3 ) Recommended adult dose: 0.8 mg per kg of ideal body weight or actual body weight, whichever is lower, administered intravenously via a central venous catheter as a two-hour infusion every six hours for four consecutive days for a total of 16 doses. ( 2.1 )

2.1Initial Dosing Information Administer Busulfan Injection in combination with cyclophosphamide as a conditioning regimen prior to bone marrow or peripheral blood progenitor cell replacement. For patients weighing more than 12 kg, the recommended doses are: Busulfan Injection 0.8 mg per kg (ideal body weight or actual body weight, whichever is lower) intravenously via a central venous catheter as a two-hour infusion every six hours for four consecutive days for a total of 16 doses (Days -7, -6, -5 and -4). Cyclophosphamide 60 mg per kg intravenously as a one-hour infusion on each of two days beginning no sooner than six hours following the 16 th dose of Busulfan Injection (Days -3 and -2).

Administer hematopoietic progenitor cells on Day 0. Premedicate patients with anticonvulsants (e.g., benzodiazepines, phenytoin, valproic acid or levetiracetam) to prevent seizures reported with the use of high dose Busulfan Injection. Administer anticonvulsants 12 hours prior to Busulfan Injection to 24 hours after the last dose of Busulfan Injection [see Warnings and Precautions (5.2) ] .

Administer antiemetics prior to the first dose of Busulfan Injection and continue on a fixed schedule through Busulfan Injection administration. Busulfan Injection clearance is best predicted when the Busulfan Injection dose is administered based on adjusted ideal body weight. Dosing Busulfan Injection based on actual body weight, ideal body weight or other factors can produce significant differences in Busulfan Injection clearance among lean, normal and obese patients.

Calculate ideal body weight (IBW) as follows (height in cm, and weight in kg): Men: IBW (kg)=50+0.91× (height in cm -152) Women: IBW (kg)=45+0.91× (height in cm -152) For obese or severely obese patients, base Busulfan Injection dosing on adjusted ideal body weight (AIBW): AIBW= IBW +0.25× (actual weight -IBW).

2.2Preparation and Administration Precautions Busulfan Injection is incompatible with polycarbonate. Do not use any infusion components (syringes, filter needles, intravenous tubing, etc.) containing polycarbonate with Busulfan Injection. Use an administration set with minimal residual hold-up volume (2 mL to 5 mL) for product administration.

Busulfan Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures. Skin reactions may occur with accidental exposure.

Use gloves when preparing Busulfan Injection. If Busulfan Injection or diluted Busulfan Injection solution contacts the skin or mucosa, wash the skin or mucosa thoroughly with water. Visually inspect parenteral drug products for particulate matter and discoloration prior to administration whenever the solution and container permit.

Do not use if particulate matter is seen in the Busulfan Injection vial.

2.3Preparation for Intravenous Administration Busulfan Injection must be diluted prior to intravenous infusion with either 0.9% Sodium Chloride Injection, USP (normal saline) or 5% Dextrose Injection, USP (D5W). The diluent quantity should be 10 times the volume of Busulfan Injection, so that the final concentration of busulfan is approximately 0.5 mg per mL. Calculation of the dose for a 70 kg patient would be performed as follows: (70 kg patient) × (0.8 mg per kg) ÷ (6 mg per mL) =9.3 mL Busulfan Injection (56 mg total dose).

To prepare the final solution for infusion, add 9.3 mL of Busulfan Injection to 93 mL of diluent (normal saline or D5W) as calculated below: (9.3 mL Busul… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths 37 words ▾

3 DOSAGE FORMS AND STRENGTHS Injection: 60 mg/10 mL (6 mg/mL) as a clear, colorless, sterile, solution in a single-dose vial for intravenous use only . Injection: 60 mg/10 mL (6 mg/mL) single-dose vial. ( 3 )

⛔ Contraindications 37 words ▾

4 CONTRAINDICATIONS Busulfan Injection is contraindicated in patients with a history of hypersensitivity to any of its components. Busulfan Injection is contraindicated in patients with a history of hypersensitivity to any of its components. ( 4 )

⚠️ Warnings and Cautions ~3 min read ▾

5 WARNINGS AND PRECAUTIONS Seizures: Initiate anticonvulsant prophylactic therapy prior to treatment with Busulfan Injection. Monitor patients with history of seizure disorder, head trauma or receiving epileptogenic drugs. ( 5.2 ) Hepatic Veno-Occlusive Disease (HVOD): Increased risk of developing HVOD at AUC greater than 1,500 µM∙min.

Monitor serum transaminases, alkaline phosphatase and bilirubin daily. ( 5.3 ) Embryo-fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception.

( 5.4 , 8.1 , 8.3 ) Cardiac tamponade has been reported in pediatric patients with thalassemia who received high doses of oral busulfan and cyclophosphamide. Abdominal pain and vomiting preceded the tamponade in most patients. ( 5.5 )

5.1Myelosuppression The most frequent serious consequence of treatment with Busulfan Injection at the recommended dose and schedule is prolonged myelosuppression, occurring in all patients (100%). Severe granulocytopenia, thrombocytopenia, anemia, or any combination thereof may develop. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression.

Monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated. Absolute neutrophil counts dropped below 0.5×10 9 /L at a median of 4 days post-transplant in 100% of patients treated in the Busulfan Injection clinical trial. The absolute neutrophil count recovered at a median of 13 days following allogeneic transplantation when prophylactic filgrastim was used in the majority of patients.

Thrombocytopenia (less than 25,000/mm 3 or requiring platelet transfusion) occurred at a median of 5 to 6 days in 98% of patients. Anemia (hemoglobin less than 8.0 g/dL) occurred in 69% of patients. Use antibiotic therapy and platelet and red blood cell support when medically indicated.

5.2Seizures Seizures have been reported in patients receiving high-dose oral busulfan at doses producing plasma drug levels similar to those achieved following the recommended dosage of Busulfan Injection. Despite prophylactic therapy with phenytoin, one seizure (1/42 patients) was reported during an autologous transplantation clinical trial of Busulfan Injection. This episode occurred during the cyclophosphamide portion of the conditioning regimen, 36 hours after the last Busulfan Injection dose.

Initiate phenytoin therapy or any other alternative anti-convulsant prophylactic therapy (e.g., benzodiazepines, valproic acid or levetiracetam) prior to Busulfan Injection treatment [see Dosage and Administration (2.1) ] . Use caution when administering the recommended dose of Busulfan Injection to patients with a history of a seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs.

5.3Hepatic Veno-Occlusive Disease (HVOD) Current literature suggests that high busulfan area under the plasma concentration verses time curve (AUC) values (greater than 1,500 µM∙min) may be associated with an increased risk of developing HVOD. Patients who have received prior radiation therapy, greater than or equal to three cycles of chemotherapy, or a prior progenitor cell transplant may be at an increased risk of developing HVOD with the recommended Busulfan Injection dose and regimen. Based on clinical examination and laboratory findings, HVOD was diagnosed in 8% (5/61) of patients treated with Busulfan Injection in the setting of allogeneic transplantation, was fatal in 2/5 cases (40%), and yielded an overall mortality from HVOD in the entire study population of 2/61 (3%).

Three of the five patients diagnosed with HVOD were retrospectively found to meet the Jones' criteria. The incidence of HVOD reported in the literature from the randomized, controlled trials was 7.7% to 12% [see Clinical Studies (14) ]. Monitor serum transaminases, alkaline phosphatase, and bilirubin dail… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Myelosuppression [see Warnings and Precautions (5.1) ] Seizures [see Warnings and Precautions (5.2) ] Hepatic Veno-Occlusive Disease (HVOD) [see Warnings and Precautions (5.3) ] Embryo-fetal Toxicity [see Warnings and Precautions (5.4) ] Cardiac Tamponade [see Warnings and Precautions (5.5) ] Bronchopulmonary Dysplasia [see Warnings and Precautions (5.6) ] Cellular Dysplasia [see Warnings and Precautions (5.7) ] Most common adverse reactions (incidence > 60%) were: myelosuppression, nausea, stomatitis, vomiting, anorexia, diarrhea, insomnia, fever, hypomagnesemia, abdominal pain, anxiety, headache, hyperglycemia and hypokalemia.

( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reaction information is primarily derived from the clinical study (N=61) of Busulfan Injection and the data obtained for high-dose oral busulfan conditioning in the setting of randomized, controlled trials identified through a literature review.

In the Busulfan Injection allogeneic stem cell transplantation clinical trial, all patients were treated with Busulfan Injection 0.8 mg per kg as a two-hour infusion every six hours for 16 doses over four days, combined with cyclophosphamide 60 mg per kg × 2 days. Ninety-three percent (93%) of evaluable patients receiving this dose of Busulfan Injection maintained an AUC less than 1,500 µM∙min for dose 9, which has generally been considered the level that minimizes the risk of HVOD. Table 1 lists the non-hematologic adverse reactions events through Bone Marrow Transplantation (BMT) Day+28 at a rate greater than or equal to 20% in patients treated with Busulfan Injection prior to allogeneic hematopoietic cell transplantation.

Table 1: Summary of the Incidence (greater than or equal to 20%) of Non-Hematologic Adverse Reactions through BMT Day +28 in Patients who Received Busulfan Injection Prior to Allogeneic Hematopoietic Progenitor Cell Transplantation Non-Hematological Adverse Reactions Includes all reported adverse reactions regardless of severity (toxicity grades 1–4) Percent Incidence BODY AS A WHOLE Fever 80 Headache 69 Asthenia 51 Chills 46 Pain 44 Edema General 28 Allergic Reaction 26 Chest Pain 26 Inflammation at Injection Site 25 Back Pain 23 CARDIOVASCULAR SYSTEM Tachycardia 44 Hypertension 36 Thrombosis 33 Vasodilation 25 DIGESTIVE SYSTEM Nausea 98 Stomatitis (Mucositis) 97 Vomiting 95 Anorexia 85 Diarrhea 84 Abdominal Pain 72 Dyspepsia 44 Constipation 38 Dry Mouth 26 Rectal Disorder 25 Abdominal Enlargement 23 METABOLIC AND NUTRITIONAL SYSTEM Hypomagnesemia 77 Hyperglycemia 66 Hypokalemia 64 Hypocalcemia 49 Hyperbilirubinemia 49 Edema 36 SGPT Elevation 31 Creatinine Increased 21 NERVOUS SYSTEM Insomnia 84 Anxiety 72 Dizziness 30 Depression 23 RESPIRATORY SYSTEM Rhinitis Lung Disorder Cough Epistaxis Dyspnea 44 34 28 25 25 SKIN AND APPENDAGES Rash 57 Pruritus 28 Additional Adverse Reactions by Body System Hematologic: Prolonged prothrombin time Gastrointestinal: Esophagitis, ileus, hematemesis, pancreatitis, rectal discomfort Hepatic: Alkaline phosphatase increases, jaundice, hepatomegaly Graft-versus-host disease: Graft-versus-host disease.

There were 3 deaths (5%) attributed to GVHD. Edema: Hypervolemia, or documented weight increase Infection: Infection, pneumonia (fatal in one patient and life-threatening in 3% of patients) Cardiovascular: Arrhythmia, atrial fibrillation, ventricular extrasystoles, third degree heart block, thrombosis (all episodes were associated with the central venous catheter), hy… [Excerpted — this section continues on DailyMed.]

🔄 Drug Interactions 218 words ▾

7 DRUG INTERACTIONS Drugs that Decrease Busulfan Injection Clearance: Metronidazole, itraconazole, iron chelating agents, acetaminophen. ( 7.1 ) Drugs that Increase Busulfan Injection Clearance: Phenytoin. ( 7.2 )

7.1Drugs that Decrease Busulfan Injection Clearance Itraconazole decreases busulfan clearance by up to 25%. Metronidazole decreases the clearance of busulfan to a greater extent than does itraconazole; metronidazole coadministration has been associated with increased busulfan toxicity. Fluconazole (200 mg) has been used with Busulfan Injection.

Decreased clearance of busulfan was observed with concomitant use with deferasirox. The mechanism of this interaction is not fully elucidated. Discontinue iron chelating agents well in advance of administration of Busulfan Injection to avoid increased exposure to busulfan.

Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to (less than 72 hours) or concurrent with Busulfan Injection may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.

7.2Drugs that Increase Busulfan Injection Clearance Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase. Since the pharmacokinetics of Busulfan Injection were studied in patients treated with phenytoin, the clearance of Busulfan Injection at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed. ( 8.2 )

8.1Pregnancy Risk Summary Busulfan Injection can cause fetal harm when administered to a pregnant woman based on animal data. Busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. The solvent, DMA, may also cause fetal harm when administered to a pregnant woman.

In rats, DMA doses of approximately 40% of the daily dose of DMA in the Busulfan Injection dose on a mg/m 2 basis given during organogenesis caused significant developmental anomalies ( see Data ) . There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus.

The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. Animal Data Following administration during organogenesis in animals, busulfan caused malformations and anomalies, including significant alterations in the musculoskeletal system, body weight gain, and size.

In pregnant rats, busulfan produced sterility in both male and female offspring due to the absence of germinal cells in the testes and ovaries. The solvent, N,N-dimethylacetamide (DMA), administered to rats at doses of 400 mg/kg/day (about 40% of the daily dose of DMA in the Busulfan Injection dose on a mg/m 2 basis) during organogenesis caused significant developmental anomalies. The most striking abnormalities included anasarca, cleft palate, vertebral anomalies, rib anomalies, and serious anomalies of the vessels of the heart.

8.2Lactation Risk Summary It is not known whether busulfan is present in human milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity shown for busulfan in human and animal studies, discontinue breastfeeding during treatment with Busulfan Injection.

8.3Females and Males of Reproductive Potential Contraception Females Busulfan Injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Advise females of reproductive potential to use effective contraception during treatment with Busulfan Injection and for 6 months following cessation of therapy. Males Busulfan Injection may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities.

Males with female sexual partners of reproductive potential should use effective contraception during treatment with Busulfan Injection and for 3 months after cessation of therapy [see Nonclinical Toxicology (13.1) ]. Infertility Females Ovarian suppression and amenorrhea commonly occur in premenopausal women undergoing chronic, low-dose busulfan therapy for chronic myelogenous leukemia. Busulfan Injection may cause temporary or permanent infertility in prepubertal girls or in females of child-bearing potential treated with high-dose Busulfan Injection in the conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation.

Males Sterility, azoospermia, and testicular atrophy have been reported in male patients.

8.4Pediatric Use The effectiveness of Busulfan Injection in the treatment of CML has not been specifically studied in pediatric patients. An open-label, uncontrolled study evaluated the pharmacokinetics of Busulfan Injection in 24 pediatric patients receiving busulfan as part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic (N=15) or non-malignant diseases (N=9). Patients ranged in age from 5 months to 16 years (median 3 years).

Busulfan Injection dosing was targeted to achieve an area under the plasma concentration curve (AUC) of 900–1350 µM∙min with an initial dose of 0.8 mg per kg or 1.0 mg per kg (based on Actual Body Weight (ABW)) if the patient was greater than… [Excerpted — this section continues on DailyMed.]

🤰 Pregnancy ~1 min read ▾

8.1Pregnancy Risk Summary Busulfan Injection can cause fetal harm when administered to a pregnant woman based on animal data. Busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. The solvent, DMA, may also cause fetal harm when administered to a pregnant woman.

In rats, DMA doses of approximately 40% of the daily dose of DMA in the Busulfan Injection dose on a mg/m 2 basis given during organogenesis caused significant developmental anomalies ( see Data ) . There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus.

The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. Animal Data Following administration during organogenesis in animals, busulfan caused malformations and anomalies, including significant alterations in the musculoskeletal system, body weight gain, and size.

In pregnant rats, busulfan produced sterility in both male and female offspring due to the absence of germinal cells in the testes and ovaries. The solvent, N,N-dimethylacetamide (DMA), administered to rats at doses of 400 mg/kg/day (about 40% of the daily dose of DMA in the Busulfan Injection dose on a mg/m 2 basis) during organogenesis caused significant developmental anomalies. The most striking abnormalities included anasarca, cleft palate, vertebral anomalies, rib anomalies, and serious anomalies of the vessels of the heart.

🧒 Pediatric Use ~3 min read ▾

8.4Pediatric Use The effectiveness of Busulfan Injection in the treatment of CML has not been specifically studied in pediatric patients. An open-label, uncontrolled study evaluated the pharmacokinetics of Busulfan Injection in 24 pediatric patients receiving busulfan as part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic (N=15) or non-malignant diseases (N=9). Patients ranged in age from 5 months to 16 years (median 3 years).

Busulfan Injection dosing was targeted to achieve an area under the plasma concentration curve (AUC) of 900–1350 µM∙min with an initial dose of 0.8 mg per kg or 1.0 mg per kg (based on Actual Body Weight (ABW)) if the patient was greater than 4 or less than or equal to 4 years, respectively. The dose was adjusted based on plasma concentration after completion of dose 1. Patients received Busulfan Injection doses every six hours as a two-hour infusion over four days for a total of 16 doses, followed by cyclophosphamide 50 mg per kg once daily for four days.

After one rest day, hematopoietic progenitor cells were infused. All patients received phenytoin as seizure prophylaxis. The target AUC (900–1350±5% µM∙min) for Busulfan Injection was achieved at dose 1 in 71% (17/24) of patients.

Steady state pharmacokinetic testing was performed at dose 9 and 13. Busulfan Injection levels were within the target range for 21 of 23 evaluable patients. All 24 patients experienced neutropenia (absolute neutrophil count (ANC) less than 0.5×10 9 /L) and thrombocytopenia (platelet transfusions or platelet count less than 20,000/mm 3 ).

Seventy-nine percent (19/24) of patients experienced lymphopenia (absolute lymphocyte count less than 0.1×10 9 ). In 23 patients, the ANC recovered to greater than 0.5×10 9 /L (median time to recovery = BMT day +13; range = BMT day +9 to +22). One patient who died on day +20 had not recovered to an ANC >0.5×10 9 /L.

Four (17%) patients died during the study. Two patients died within 28 days of transplant; one with pneumonia and capillary leak syndrome, and the other with pneumonia and veno-occlusive disease. Two patients died prior to day 100; one due to progressive disease and one due to multi-organ failure.

Adverse reactions were reported in all 24 patients during the study period (BMT day -10 through BMT day +28) or post-study surveillance period (day +29 through +100). These included vomiting (100%), nausea (83%), stomatitis (79%), HVOD (21%), graft-versus host disease (GVHD) (25%), and pneumonia (21%). Based on the results of this 24-patient clinical trial, a suggested dosing regimen of Busulfan Injection in pediatric patients is shown in the following dosing nomogram: Busulfan Injection Dosing Nomogram Patient's Actual Body Weight (ABW) Busulfan Injection Dosage less than or equal to 12 kgs 1.1 (mg per kg) greater than 12 kgs 0.8 (mg per kg) Simulations based on a pediatric population pharmacokinetic model indicate that approximately 60% of pediatric patients will achieve a target Busulfan Injection exposure (AUC) between 900 to 1350 µM∙min with the first dose of Busulfan Injection using this dosing nomogram.

Therapeutic drug monitoring and dose adjustment following the first dose of Busulfan Injection is recommended. Dose Adjustment Based on Therapeutic Drug Monitoring Instructions for measuring the AUC of busulfan at dose 1 (see Blood Sample Collection for AUC Determination ) and the formula for adjustment of subsequent doses to achieve the desired target AUC (1125 µM∙min), are provided below. Adjusted dose (mg) = Actual Dose (mg) × Target AUC (µM∙min)/Actual AUC (µM∙min) For example, if a patient received a dose of 11 mg busulfan and if the corresponding AUC measured was 800 µM∙min, for a target AUC of 1125 µM∙min, the target mg dose would be: Mg dose =11 mg × 1125 µM∙min /800 µM∙min =15.5 mg Busulfan Injection dose adjustment may be made using this formula and instructions below.

Blood Sample Coll… [Excerpted — this section continues on DailyMed.]

🧓 Geriatric Use 28 words ▾

8.5Geriatric Use Clinical studies of Busulfan Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

🆘 Overdosage 161 words ▾

10 OVERDOSAGE There is no known antidote to Busulfan Injection other than hematopoietic progenitor cell transplantation. In the absence of hematopoietic progenitor cell transplantation, the recommended dosage for Busulfan Injection would constitute an overdose of busulfan. The principal toxic effect is profound bone marrow hypoplasia/aplasia and pancytopenia, but the central nervous system, liver, lungs, and gastrointestinal tract may be affected.

Monitor hematologic status closely and institute vigorous supportive measures as medically indicated. Survival after a single 140 mg dose of Myleran ® Tablets in an 18 kg, 4-year old child has been reported. Inadvertent administration of a greater than normal dose of oral busulfan (2.1 mg per kg; total dose of 23.3 mg per kg) occurred in a 2-year old child prior to a scheduled bone marrow transplant without sequelae.

An acute dose of 2.4 g was fatal in a 10-year old boy. There is one report that busulfan is dialyzable, thus dialysis should be considered in the case of overdose.

🧬 Clinical Pharmacology ~2 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of a four-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This produces reactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity of busulfan.

12.3Pharmacokinetics The pharmacokinetics of Busulfan Injection were studied in 59 patients participating in a prospective trial of a Busulfan­ Injection-cyclophosphamide preparatory regimen prior to allogeneic hematopoietic progenitor stem cell transplantation. Patients received 0.8 mg/kg Busulfan Injection every six hours, for a total of 16 doses over four days. Fifty-five of fifty-nine patients (93%) administered Busulfan Injection maintained AUC values below the target value (less than 1500 μM∙min).

Table 3: Steady State Pharmacokinetic Parameters Following Busulfan Injection Infusion (0.8 mg per kg; N=59) Mean CV (%) Range C max (ng per mL) 1222 18 496 to 1684 AUC (μM∙min) 1167 20 556 to 1673 CL (mL per min per kg) Clearance normalized to actual body weight for all patients. 2.52 25 1.49 to

4.31Busulfan Injection pharmacokinetics showed consistency between dose 9 and dose 13 as demonstrated by reproducibility of steady state C max and a low coefficient of variation for this parameter. Distribution: Busulfan achieves concentrations in the cerebrospinal fluid approximately equal to those in plasma. Busulfan primarily binds to albumin (Mean ± standard deviation=32.4 ± 2.2%).

Metabolism: Busulfan is predominantly metabolized by conjugation with glutathione, both spontaneously and by glutathione S-transferase (GST) catalysis. This conjugate undergoes extensive oxidative metabolism in the liver. Excretion: Following administration of 14 C-labeled busulfan to humans, approximately 30% of the radioactivity was excreted into the urine over 48 hours; negligible amounts were recovered in feces.

Specific Populations Pediatric Patients: In a pharmacokinetic study of Busulfan Injection in 24 pediatric patients, the population pharmacokinetic (PPK) estimates of Busulfan Injection for clearance (CL) and volume of distribution (V) were determined. For actual body weight, PPK estimates of CL and V were

4.04L/hr per 20 kg (3.37 mL per min per kg; interpatient variability 23%); and

12.8L per 20 kg (0.64 L per kg; interpatient variability 11%).

🧬 Mechanism of Action 59 words ▾

12.1Mechanism of Action Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of a four-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This produces reactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity of busulfan.

📦 How Supplied / Storage and Handling 190 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1How Supplied Busulfan Injection is packaged as a sterile solution in 10 mL single-dose clear glass vials. Busulfan Injection is available as follows: Unit of Sale Concentration NDC 0409-1112-01 Carton containing 8 Single-dose vials 60 mg/10 mL (6 mg/mL)

16.2Storage and Handling Unopened vials of Busulfan Injection must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F). Discard unused portion. Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP is stable at room temperature (25°C) for up to 8 hours but the infusion must be completed within that time.

Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP is stable at refrigerated conditions (2°C to 8°C) for up to 12 hours but the infusion must be completed within that time. Busulfan Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures 1 .

16.1How Supplied Busulfan Injection is packaged as a sterile solution in 10 mL single-dose clear glass vials. Busulfan Injection is available as follows: Unit of Sale Concentration NDC 0409-1112-01 Carton containing 8 Single-dose vials 60 mg/10 mL (6 mg/mL)

📦 Storage and Handling 105 words ▾

16.2Storage and Handling Unopened vials of Busulfan Injection must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F). Discard unused portion. Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP is stable at room temperature (25°C) for up to 8 hours but the infusion must be completed within that time.

Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP is stable at refrigerated conditions (2°C to 8°C) for up to 12 hours but the infusion must be completed within that time. Busulfan Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures 1 .

📋 Description 138 words ▾

11 DESCRIPTION Busulfan is a bifunctional alkylating agent known chemically as 1,4-butanediol, dimethanesulfonate. The molecular formula of busulfan is CH 3 SO 2 O(CH 2 ) 4 OSO 2 CH 3 with a molecular weight of 246 g/mole. Busulfan has the following chemical structure: Busulfan Injection is supplied as a clear, colorless, sterile, solution in 10 mL single-dose vials for intravenous administration upon dilution.

Each vial contains 60 mg of busulfan in N,N-dimethylacetamide (DMA), 3.3 mL and Polyethylene Glycol 400, NF 6.7 mL. The solubility of busulfan in water is 0.1 g per L and the pH of Busulfan Injection diluted to approximately 0.5 mg per mL busulfan in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP as recommended for infusion reflects the pH of the diluent used and ranges from 3.4 to 3.9. Chemical Structure

💬 Information for Patients ~2 min read ▾

17 PATIENT COUNSELING INFORMATION Myelosuppression Advise patients of the possibility of developing low blood cell counts and the need for hematopoietic progenitor cell infusion. Instruct patients to immediately report to their healthcare provider if fever develops [see Warnings and Precautions (5.1) ]. Seizures Advise patients of the possibility of seizures and that they will be given medication to prevent them.

Patients should be asked to report a history of seizure or head trauma [see Warnings and Precautions (5.2) ]. Hepatic Veno-Occlusive Disease (HVOD) Advise patients of the risks associated with the use of Busulfan Injection as well as the plan for regular blood monitoring during therapy. Specifically inform patients of the following: The risk of veno-occlusive liver disease [see Warnings and Precautions (5.3) ].

Embryo-fetal Toxicity Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1) ] . Females of Reproductive Potential Advise females of reproductive potential to use effective contraception during treatment with Busulfan Injection and for 6 months following cessation of therapy [see Use in Specific Populations (8.3) ] . Males of Reproductive Potential Advise males with female sexual partners of reproductive potential to use effective contraception during treatment with Busulfan Injection and for 3 months following cessation of therapy [see Use in Specific Populations (8.3) ] .

Lactation Advise females to discontinue breastfeeding during treatment with Busulfan Injection [see Use in Specific Populations (8.2) ]. Infertility Advise females and males of reproductive potential that Busulfan Injection may cause temporary or permanent infertility [see Use in Specific Populations (8.3) ]. Cardiac Tamponade Advise patients of the risk of cardiac tamponade.

Instruct patients to report to their healthcare provider symptoms of abdominal pain and vomiting [see Warnings and Precautions (5.5) ]. Bronchopulmonary Dysplasia Advise patients of the possibility of bronchopulmonary dysplasia with pulmonary fibrosis with chronic Busulfan Injection therapy. Instruct patients to report symptoms of shortness of breath and cough to their healthcare provider.

These symptoms could occur several months or years after therapy with Busulfan Injection [see Warnings and Precautions (5.6) ].

🧬 Pharmacokinetics ~1 min read ▾

12.3Pharmacokinetics The pharmacokinetics of Busulfan Injection were studied in 59 patients participating in a prospective trial of a Busulfan­ Injection-cyclophosphamide preparatory regimen prior to allogeneic hematopoietic progenitor stem cell transplantation. Patients received 0.8 mg/kg Busulfan Injection every six hours, for a total of 16 doses over four days. Fifty-five of fifty-nine patients (93%) administered Busulfan Injection maintained AUC values below the target value (less than 1500 μM∙min).

Table 3: Steady State Pharmacokinetic Parameters Following Busulfan Injection Infusion (0.8 mg per kg; N=59) Mean CV (%) Range C max (ng per mL) 1222 18 496 to 1684 AUC (μM∙min) 1167 20 556 to 1673 CL (mL per min per kg) Clearance normalized to actual body weight for all patients. 2.52 25 1.49 to

4.31Busulfan Injection pharmacokinetics showed consistency between dose 9 and dose 13 as demonstrated by reproducibility of steady state C max and a low coefficient of variation for this parameter. Distribution: Busulfan achieves concentrations in the cerebrospinal fluid approximately equal to those in plasma. Busulfan primarily binds to albumin (Mean ± standard deviation=32.4 ± 2.2%).

Metabolism: Busulfan is predominantly metabolized by conjugation with glutathione, both spontaneously and by glutathione S-transferase (GST) catalysis. This conjugate undergoes extensive oxidative metabolism in the liver. Excretion: Following administration of 14 C-labeled busulfan to humans, approximately 30% of the radioactivity was excreted into the urine over 48 hours; negligible amounts were recovered in feces.

Specific Populations Pediatric Patients: In a pharmacokinetic study of Busulfan Injection in 24 pediatric patients, the population pharmacokinetic (PPK) estimates of Busulfan Injection for clearance (CL) and volume of distribution (V) were determined. For actual body weight, PPK estimates of CL and V were

4.04L/hr per 20 kg (3.37 mL per min per kg; interpatient variability 23%); and

12.8L per 20 kg (0.64 L per kg; interpatient variability 11%).

🔬 Clinical Studies ~3 min read ▾

14 CLINICAL STUDIES Documentation of the safety and efficacy of busulfan as a component of a conditioning regimen prior to allogeneic hematopoietic progenitor cell reconstitution is derived from two sources: i) analysis of a prospective clinical trial of Busulfan Injection that involved 61 patients diagnosed with various hematologic malignancies, and ii) the published reports of randomized, controlled trials that employed high-dose oral busulfan as a component of a conditioning regimen for transplantation, which were identified in a literature review of five established commercial databases.

Prospective Clinical Trial of Busulfan Injection: The prospective trial was a single-arm, open-label study in 61 patients who received Busulfan Injection as part of a conditioning regimen for allogeneic hematopoietic stem cell transplantation. The study included patients with acute leukemia past first remission (first or subsequent relapse), with high-risk first remission, or with induction failure; chronic myelogenous leukemia (CML) in chronic phase, accelerated phase, or blast crisis; primary refractory or resistant relapsed Hodgkin's disease or non-Hodgkin's lymphoma; and myelodysplastic syndrome.

Forty-eight percent of patients (29/61) were heavily pretreated, defined as having at least one of the following: prior radiation, greater than or equal to 3 prior chemotherapeutic regimens, or prior hematopoietic stem cell transplant. Seventy-five percent of patients (46/61) were transplanted with active disease. Patients received 16 Busulfan Injection doses of 0.8 mg per kg every 6 hours as a two-hour infusion for 4 days, followed by cyclophosphamide 60 mg per kg once per day for two days (BuCy2 regimen).

All patients received 100% of their scheduled Busulfan Injection regimen. No dose adjustments were made. After one rest day, allogeneic hematopoietic progenitor cells were infused.

The efficacy parameters in this study were myeloablation (defined as one or more of the following: absolute neutrophil count [ANC] less than 0.5×10 9 /L, absolute lymphocyte count [ALC] less than 0.1×10 9 /L, thrombocytopenia defined as a platelet count less than 20,000/mm 3 or a platelet transfusion requirement) and engraftment (ANC greater than or equal to 0.5×10 9 /L). All patients (61/61) experienced myeloablation. The median time to neutropenia was 4 days.

All evaluable patients (60/60) engrafted at a median of 13 days post-transplant (range 9 to 29 days); one patient was considered non-evaluable because he died of a fungal pneumonia 20 days after BMT and before engraftment occurred. All but 13 of the patients were treated with prophylactic G-CSF. Evidence of donor cell engraftment and chimerism was documented in all patients who had a chromosomal sex marker or leukemic marker (43/43), and no patient with chimeric evidence of allogeneic engraftment suffered a later loss of the allogeneic graft.

There were no reports of graft failure in the overall study population. The median number of platelet transfusions per patient was 6, and the median number of red blood cell transfusions per patient was 4. Twenty-three patients (38%) relapsed at a median of 183 days post-transplant (range 36 to 406 days).

Sixty-two percent of patients (38/61) were free from disease with a median follow-up of 269 days post-transplant (range 20 to 583 days). Forty-three patients (70%) were alive with a median follow up of 288 days post-transplant (range 51 to 583 days). There were two deaths before BMT Day +28 and six additional patients died by BMT Day +100.

Ten patients (16%) died after BMT Day +100, at a median of 199 days post-transplant (range 113 to 275 days). Oral Busulfan Literature Review: Four publications of randomized, controlled trials that evaluated a high-dose oral busulfan-containing conditioning regimen (busulfan 4 mg/kg/d ×4 days + cyclophosphamide 60 mg/kg/d ×2 days) for allogeneic transplantation in the setting of CML were identified. Two of the studies (Clift and De… [Excerpted — this section continues on DailyMed.]

🧪 Nonclinical Toxicology 194 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Busulfan is a mutagen and a clastogen. In in vitro tests it caused mutations in Salmonella typhimurium and Drosophila melanogaster . Chromosomal aberrations induced by busulfan have been reported in vivo (rats, mice, hamsters, and humans) and in vitro (rodent and human cells).

The intravenous administration of busulfan (48 mg/kg given as biweekly doses of 12 mg/kg, or 30% of the total Busulfan Injection dose on a mg/m 2 basis) has been shown to increase the incidence of thymic and ovarian tumors in mice. Busulfan depleted oocytes of female rats and induced sterility in male rats and hamsters. The solvent DMA may also impair fertility.

A DMA daily dose of 0.45 g/kg/day given to rats for nine days (equivalent to 44% of the daily dose of DMA contained in the recommended dose of Busulfan Injection on a mg/m 2 basis) significantly decreased spermatogenesis in rats. A single subcutaneous dose of 2.2 g/kg (27% of the total DMA dose contained in Busulfan Injection on a mg/m 2 basis) four days after insemination terminated pregnancy in 100% of tested hamsters [see Use in Specific Populations (8.3) ].

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 191 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Busulfan is a mutagen and a clastogen. In in vitro tests it caused mutations in Salmonella typhimurium and Drosophila melanogaster . Chromosomal aberrations induced by busulfan have been reported in vivo (rats, mice, hamsters, and humans) and in vitro (rodent and human cells).

The intravenous administration of busulfan (48 mg/kg given as biweekly doses of 12 mg/kg, or 30% of the total Busulfan Injection dose on a mg/m 2 basis) has been shown to increase the incidence of thymic and ovarian tumors in mice. Busulfan depleted oocytes of female rats and induced sterility in male rats and hamsters. The solvent DMA may also impair fertility.

A DMA daily dose of 0.45 g/kg/day given to rats for nine days (equivalent to 44% of the daily dose of DMA contained in the recommended dose of Busulfan Injection on a mg/m 2 basis) significantly decreased spermatogenesis in rats. A single subcutaneous dose of 2.2 g/kg (27% of the total DMA dose contained in Busulfan Injection on a mg/m 2 basis) four days after insemination terminated pregnancy in 100% of tested hamsters [see Use in Specific Populations (8.3) ].

📚 References 13 words ▾

15 REFERENCES 1.OSHA Hazardous Drugs. OSHA. [Accessed on June 18, 2014 from http://www.osha.gov/SLTC/hazardousdrugs/index.html]

📄 Package Label / Principal Display Panel 137 words ▾

PRINCIPAL DISPLAY PANEL - 10 mL Vial Label NDC 0409-1112-10 Rx only Busulfan Injection 60 mg/10 mL (6 mg/mL) FOR INTRAVENOUS INFUSION ONLY Caution: Must be diluted before use. Sterile Single-Dose Vial CYTOTOXIC AGENT Hospira PRINCIPAL DISPLAY PANEL - 10 mL Vial Label

PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton NDC 0409-1112-10 Rx only Busulfan Injection 60 mg/10 mL (6 mg/mL) FOR INTRAVENOUS INFUSION ONLY Caution: Must be diluted before use. Sterile Single-Dose Vial CYTOTOXIC AGENT Hospira PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton

PRINCIPAL DISPLAY PANEL - 8 Vial Carton NDC-0409-1112-01 Contains 8 of NDC 0409-1112-10 Eight 10 mL (6 mg/mL) Single-Dose Vials Busulfan Injection 60 mg/10 mL (6 mg/mL) Sterile Single-Dose Vial FOR INTRAVENOUS INFUSION ONLY Caution: Must be diluted before use. CYTOTOXIC AGENT Rxonly Hospira PRINCIPAL DISPLAY PANEL - 8 Vial Carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)

Medicare Part D (outpatient prescription) spending for Myleran (matched by generic name) — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Myleran. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Total Part D spend
$200.4K
Claims incl. refills
25
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$8,017.72
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Busulfan — the ingredient across all brands.

Top reported reactions

Mucosal Inflammation1,111
Graft Versus Host Disease914
Venoocclusive Liver Disease875
Cytomegalovirus Infection873
Febrile Neutropenia863
Acute Graft Versus Host Disease825
Pyrexia816

Age at onset

Neonate54
Infant290
Child796
Adolescent226
Adult1,750
Elderly134

Reporter sex

15,641 reports
Male · 56%
Female · 42%
Unknown · 2%

Serious outcomes

Death4,592
Hospitalization3,232
Life-threatening1,211
Disabling136
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,532 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk ✓ Available
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Hospira, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Hospira, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code J0594 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00409-1109-01 · Hospira, 00409-1141-02 · Hospira, →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.